- Dr. Fatih M. Uckun
- Chief Medical Officer and Chief Scientific Officer, Reven Pharmaceuticals, Westminster, CO, USA.
Website | E-mail
Special Issue Introduction
Multiple myeloma (MM) is the second most common hematologic malignancy after non-Hodgkin’s lymphoma. Intrinsic and acquired drug resistance of cancer cells to standard drugs is a major obstacle for a more successful survival outcome of MM patients treated on contemporary clinical protocols. Multiple molecular mechanisms have been implicated for the emergence of multi-drug resistance in MM and several new treatment strategies have been developed against druggable molecular targets to overcome such drug resistance. There are highly promising new targeted therapeutics with anti-MM activity in clinical pipeline, including tyrosine kinase inhibitors, inhibitors of anti-apoptotic proteins, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, and various cell therapy platforms.
The primary purpose of this special issue on “Drug Targets and Resistance Mechanisms in Multiple Myeloma” is to collect new and transformative information regarding new insights about the mechanisms of drug resistance in MM and the role of the tumor micro-environment in treatment failures. We are particularly interested in papers on precision medicines with a well-defined and preferably unique mechanism of action that show a high clinical impact potential. Manuscripts detailing proof of concept studies in clinical settings are particularly welcome.
Submission Deadline31 Jul 2021